Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation ...

Eli Lilly and Co. is expanding its real estate footprint in Boston’s Seaport district with a new lease for 75,000 square feet ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P.

Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...